|
| |
| Drug Development |
|
ReceptoPharm is developing proprietary
therapeutic protein products for the treatment of neurological,
viral and and autoimmune disorders. |
| »
Learn More |
|
|
| |
| CRO Services |
ReceptoPharm offers a full range of contract
research services catering to small and start-up biotech companies. |
| » Learn More |
|
|
|
ReceptoPharm was incorporated as Receptogen
in the United States under the laws of the
State of Nevada on June 4, 2001 for the
purpose, among other things, of developing
and acquiring patents based upon advanced
receptor and molecular biology. The name
was changed to ReceptoPharm in April of
2003 and the company was licensed to do
business in the State of Florida.
ReceptoPharm is engaged in the discovery
and development of novel and off-patent
peptide technologies primarily for the prevention
and treatment of disease in humans. The
emphasis of ReceptoPharm's approach to the
development of new therapeutic agents is
based upon specialized receptor-binding
proteins found in nature. The Company's
primary focus is on the treatment of viral
and neurological diseases.
With its' large volume of research and
preclinical data ReceptoPharm believes it
has identified a number of therapeutic products
that have the capability to provide significant
benefits for patients with such diseases
as multiple sclerosis (MS), adrenomyeloneuropathy
(AMN), human immunodeficiency virus (HIV),
myasthenia gravis (MG), pain, and other
disorders.
ReceptoPharm's principal executive offices,
manufacturing, research and development
facilities are located Plantation, Florida. |
|
|
| |
| E-Alerts
|
| Signup to receive news and announcements
from ReceptoPharm and Nutra Pharma: |
|
|
|
|
|
|
|
